Novo Nordisk Returns To Growth, With Growing Pains

By Ben Comer, Chief Editor, Life Science Leader

Semaglutide, the active ingredient in Novo Nordisk’s Ozempic, Rybelsus, and Wegovy, has been a game changer for the 100-year-old Danish company. Novo is now entering “what we internally call chapter two of our transformation and evolution into new therapy areas,” says Doug Langa, EVP, North America operations and president of Novo Nordisk. Revenues in North America were up 41% in the first quarter of 2023, due in no small part to the growing demand for safe and effective obesity products.